Roundtable Discussion; The Future of Mineral Sands. Watch the video here.
Grace from memory they increased the dose to 16mgs but the body could not excrete the waste and the patients took on a jaundiced parlour so they stopped. They had said they could give unlimited dosage but changed their mind.
Can somebody show me where PYC is due anything on 201. There is an agreement from 2011 but George always maintained the joint venture never got going and PYC were not due anything. In the q and a Suzy referred to the RNS regarding the agreement but never confirmed if any thing due on the agreement. So we do not know. Folk on AVDFN assume they are due but until the agreement is pulled out we do not know.
Tommy85 I would take what viera says with a very large pinch of salt. I note he only posts on this Bb. So you would think if someone is investing the kind of money he says he is in Val that he would have other investments on AIM and be commenting on other BBs. Very strange.
Grace if you had been in this share as long as some you may not be of the opinion that the company was mismanaged but in fact was managed very well to the point where the company would have gone bust within months of the results of 201 coming out and the IP would have been tucked up in a brand new company owned by - well take a guess.
Some serious money being thrown at this over the last few days. I wonder if its those in the know who have funded the placements in bygone days and now realise the game is over for them and they are having a last throw of the dice. Just a thought
There is a RNS of 13th Sept 2011 no 09020 which is about a joint venture between PYC and Valipharma which is a Valirx wholly owned subsidiary to use PYC knowhow to produce a new IP to be used in progressing 201.
The RNS is not in lse backlog of RNSs. George always said the venture never took off and was never used but at present Valirx do not seem to want to clear up who owns what or if PYC will have a claim.
Perhaps someone can find the relevant RNS and put it in her for all to see